Xofigo® recommended for prostate cancer with bone metastases in an additional patient group

The National Institute for Health and Care Excellence (NICE) has recommended Xofigo^® (radium-223 dichloride) in their draft guidance for adult men with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases where docetaxel is contraindicated or is not suitable.¹

The National Institute for Health and Care Excellence (NICE) has recommended Xofigo^® (radium-223 dichloride) in their draft guidance for adult men with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases where docetaxel is contraindicated or is not suitable.¹

Radium-223 already has full NICE guidance in England for adult men with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases who have previously received docetaxel therapy 2 and this draft guidance is an extended approval to include an additional group of men.

Dr Amit Bahl, Consultant Oncologist at Bristol Cancer Institute, University Hospitals Bristol said “This news is a step forward for men with prostate cancer as there are limited treatment options available in this group of men.”

Prostate cancer is the most common cancer affecting men in the UK.³ There are about 41,700 men diagnosed with prostate cancer each year, which is more than 110 every day.⁴ In some cases prostate cancer may spread to other parts of the body, particularly the bones, in certain cases leading to debilitating pain,^3,5 and/or bone fractures.⁶

Dr Alexander Moscho, CEO Bayer UK & Ireland said, “Bayer is pleased that NICE has extended their guidance to include an additional recommendation for radium-223. NICE has already recommended radium-223 for patients post-docetaxel and this positive draft guidance marks a significant step in Bayer’s ongoing dedication to addressing unmet clinical needs in prostate cancer.”

Radium-223 is the first alpha-particle emitting radioactive therapeutic agent recommended for use for the treatment of adult men with metastatic hormone relapsed prostate cancer within the NHS. Bone metastases are a significant cause of mortality in these patients⁷ and the availability of radium-223 on the NHS will enable doctors and physicians to better manage the disease.

In the Phase III ALSYMPCA study, radium-223 dichloride was shown to significantly extend median overall survival (OS), the primary endpoint of the study. Median OS was 14.9 months for radium-223 dichloride compared to 11.3 months for placebo (HR=0.70 [95% CI, 0.58-0.83]; p<0.001).8 In addition, there was a delay in the time to first symptomatic skeletal event for patients treated with radium-223 dichloride compared to placebo (HR=0.66 [95% CI, 0.52-0.83] p<0.001).⁸

The most frequently observed adverse reactions (≥10%) in patients receiving radium-223 dichloride were diarrhoea, nausea, vomiting and thrombocytopenia.⁹

Radium-223 dichloride was approved for the treatment of adult men with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases, in November 2013 in the European Union.¹⁰

References

1. National Institute for Health and Care Excellence. NICE Final Appraisal Determination. Radium-223 dichoride for treating hormone-relapsed prostate cancer with bone metastases. Available at: https://www.nice.org.uk/guidance/ta376 [Last access August 2016]
2. National Institute for Health and Care Excellence. Radium-223 dichoride for treating hormone-relapsed prostate cancer with bone metastases. Available at: https://www.nice.org.uk/guidance/ta376/chapter/1-Recommendations [Last access August 2016]
3. MacMillan Cancer Support. About Prostate Cancer. May 2012. Available at: http://www.macmillan.org.uk/Cancerinformation/Cancertypes/Prostate/Aboutprostatecancer/Prostatecancer.aspx [Last accessed August 2016]
4. Cancer Research. Prostate Cancer Incidence. Available at: http://www.cancerresearchuk.org/about-cancer/type/prostate-cancer/about/prostate-cancer-risks-and-causes [Last accessed August 2016]
5. Halabi S et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol. 2008: 26;15:2544-2549. Available at: http://jco.ascopubs.org/content/26/15/2544.ful.pdf[Last access August 2016]
6. Prostate Cancer UK. Advanced prostate cancer: Managing symptoms. February 2015. Available at: http://prostatecanceruk.org/prostate-information/living-with-prostate-cancer/advanced-prostate-cancer-managing-symptoms [Last accessed August 2016]
7. Sathiakumar N et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer. Prostate Cancer Prostatic Dis 2011; 14(2):177-183. DOI: 10.1038/pcan.2011.7
8. Parker C et al. Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer. N Engl J Med. 2013:369;3:213-223
9. Bayer. Summary of Product Characteristics. Xofigo 1100 kBq/mL solution for injection. 2015. Available at: https://www.medicines.org.uk/emc/medicine/28471#PRODUCTINFO [Last accessed August 2016]
10. European Medicines Agency. Xofigo (radium-223 dichloride). 2015. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002653/human_med_001692.jsp&mid=WC0b01ac058001d124 [Last accessed August 2016]